Iloperidone
ایلوپریدون
🧠 Nervous SystemAtypical antipsychotic
Market / country: 🇺🇸 USA
Fanapt (US)
🧮 Dose calculator
Schizophrenia · Regimen source: FDA Fanapt · 2.1, Table 1
- • Daily titration per Table 1 (1, 2, 4, 6 mg twice daily…) to avoid orthostatic hypotension. Off >3 days: re-titrate. CYP2D6 poor metabolisers or strong CYP2D6/3A4 inhibitors: half the dose. FDA Fanapt · 2.1FDA Fanapt · 2.5FDA Fanapt · 2.2FDA Fanapt · 2.4
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Known hypersensitivity to iloperidone. FDA Fanapt · 4
Warnings
- • Boxed warning: increased mortality in elderly patients with dementia-related psychosis — not approved for this use. FDA Fanapt · Boxed Warning
- • QT prolongation; orthostatic hypotension and syncope; NMS; tardive dyskinesia; metabolic changes; leukopenia; priapism. Not recommended in severe hepatic impairment. FDA Fanapt · 5FDA Fanapt · 2.3
Formulations
- 6 mg tablet — tablet 🇺🇸 USA FDA Fanapt · 3
- 12 mg tablet — tablet 🇺🇸 USA FDA Fanapt · 3
- 1 mg tablet — tablet 🇺🇸 USA FDA Fanapt · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Fanapt · 8.1
“Risk Summary Neonates whose mothers are exposed to antipsychotic drugs, including FANAPT, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery [see Clinical Considerations ] .”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Fanapt · 8.2
“Risk Summary There is no information regarding the presence of iloperidone or its metabolites in human milk, the effects of iloperidone on a breastfed child, nor the effects of iloperidone on human milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Fanapt · 8.4
“Safety and effectiveness of FANAPT have not been established in pediatric patients.”
- 👴 Older adultsDangerous / avoid
Label: serious warning or avoid in older adults. FDA Fanapt · Boxed Warning
“Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA022192
- DailyMed (FDA label)FDA Fanapt
- MedlinePlus (NIH)Iloperidone
- WHO ATC/DDDN05AX14
- Darooyab (Iran)Iloperidone
🇮🇷 Not found in Iran list Darooyab · G-4919/Iloperidone
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Fanapt · 3FDA Fanapt · 2.1, Table 1FDA Fanapt · 2.1FDA Fanapt · 2.5FDA Fanapt · 2.2FDA Fanapt · 2.4FDA Fanapt · 4FDA Fanapt · Boxed WarningFDA Fanapt · 5FDA Fanapt · 2.3FDA Fanapt · 8.1FDA Fanapt · 8.2FDA Fanapt · 8.4FDA Fanapt · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-4919/Iloperidone
- Clinical review⚠ Unverified